- Q1 2024 Valneva SE Earnings Call TranscriptMay 07, 2024€3.41 (-1.16%)Earnings
- Full Year 2023 Valneva SE Earnings Call TranscriptMar 20, 2024€3.37 (-10.66%)Earnings
- Valneva SE Analyst Call TranscriptNov 13, 2023
- Q3 2023 Valneva SE Earnings Call TranscriptNov 09, 2023€6.18 (+0.62%)Earnings
- Half Year 2023 Valneva SE Earnings Call TranscriptSep 21, 2023€6.04 (-4.16%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Valneva SE Earnings Call TranscriptMay 04, 2023€5.31 (+26.70%)Earnings
- Full Year 2022 Valneva SE Earnings Call TranscriptMar 23, 2023€4.82 (-1.63%)Earnings
- Valneva SE Corporate Analyst Meeting TranscriptDec 06, 2022
- Q3 2022 Valneva SE Earnings Call TranscriptNov 10, 2022€7 (+4.60%)Earnings
- Half Year 2022 Valneva SE Earnings Call TranscriptAug 11, 2022€9.96 (-5.14%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Valneva SE COVID-19 Vaccine Purchase Agreement Update TranscriptMay 16, 2022
- Q1 2022 Valneva SE Earnings Call TranscriptMay 05, 2022€11.86 (+0.13%)Earnings
- Full Year 2021 Valneva SE Earnings Call TranscriptMar 24, 2022€17.35 (+1.17%)Earnings
- Valneva SE - Special Call TranscriptOct 18, 2021
- Half Year 2021 Valneva SE Earnings Call TranscriptAug 10, 2021€3.1Earnings
- Valneva SE Annual Shareholders Meeting TranscriptJun 23, 2021
- Q1 2021 Valneva SE Earnings Call TranscriptMay 20, 2021€3.1Earnings
- Full Year 2020 Valneva SE Earnings Call TranscriptFeb 25, 2021€3.1Earnings
- Q3 2020 Valneva SE Earnings Call TranscriptNov 03, 2020€3.1Earnings
- Half Year 2020 Valneva SE Earnings Call TranscriptAug 04, 2020€3.1Earnings
- Q1 2020 Valneva SE Earnings Call TranscriptMay 07, 2020€3.1Earnings
- Full Year 2019 Valneva SE Earnings Call TranscriptFeb 27, 2020€3.1Earnings
- Nine Months 2019 Valneva SE Earnings Call TranscriptOct 31, 2019€3.1Earnings
- Half Year 2019 Valneva SE Earnings Call TranscriptAug 01, 2019€3.1Earnings
- Valneva SE R&D Investor Day Presentation TranscriptJul 09, 2019
- Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call TranscriptJun 21, 2019
- Q1 2019 Valneva SE Earnings Call TranscriptMay 02, 2019€3.1Earnings
- Full Year 2018 Valneva SE Earnings Call TranscriptFeb 21, 2019€3.1Earnings
Q1 2022 Valneva SE Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the Valneva Q1 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Thomas Lingelbach, CEO of Valneva. Please go ahead.
Good day, and welcome to our quarter 1 financial results and corporate update call. Pleasure to be with you again today. Yes. So basically, the quarter 1 has again been marked by excellent progress on our clinical programs. We have been able to report further positive Phase II results for our Lyme vaccine candidates, including quite exciting first pediatric data, first ever in the world of Lyme vaccine development. And on COVID-19, our program, VLA2001, we received MHRA conditional marketing authorization in April. MHRA Emergency use authorization, including first vaccination in Bahrain. And the EMA rolling review process is still ongoing. We had
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)